STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
Pharmaceutical companies involved in the TrumpRx drug-pricing program significantly increased their lobbying efforts, spending over $130 million in 2025, while Eli Lilly paused its obesity awareness campaign in India due to regulatory concerns regarding advertising prescription medications to consumers.
The most valuable insight for someone in your role is the significant increase in lobbying efforts by pharmaceutical companies involved in the TrumpRx program, with a 23% surge in spending during 2025 as the program was being developed. This indicates a strong strategic interest from the industry in shaping drug-pricing policies and highlights the potential for future regulatory and market changes that could impact healthtech and biotech sectors, particularly for stakeholders in drug pricing and policy advocacy.